Dhipatimendi rePasi Pose

Pakutanga kwaKurume, National Medical Products Administration yakabvumidza Jaypirca® (pirtobrutinib) yekurapa varwere vakuru vane chronic lymphocytic leukemia (CLL) kana small lymphocytic lymphoma (SLL) avo vakamborapwa kamwe chete kare, kusanganisira Bruton's tyrosin...Verenga zvakawanda»

Nhau dzinonakidza dzakabuda munguva pfupi yapfuura kubva kuCenter for Drug Evaluation (CDE) yeNational Medical Products Administration yeChina: kuyedzwa kwekiriniki kweKSD-101 Injection, yakagadzirwa neHensen Bio, kwabvumidzwa. Kushandiswa kwakaratidzwa ndekwe "EBV-associated hematological tumors iyo ine...Verenga zvakawanda»

Munguva pfupi yapfuura, China National Medical Products Administration (NMPA) yakabvumidza chiratidzo chitsva cheBireociclib, mushonga mutsva weClass 1 wakagadzirwa wega neXuanzhu Biopharmaceutical. Chiratidzo chitsva ichi ndechekushandiswa pamwe chete nemushonga unodzivirira aromatase senzira yekutanga yekurapa endocrine ye ...Verenga zvakawanda»

Musi wa28 Kukadzi, 2026, National Medical Products Administration (NMPA) yakabvumidza zviri pamutemo kutengeswa kweJMKX001899 sulfate yekurapa varwere vakuru vane KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) avo vakamborapwa kamwe chete kare. JMKX00189...Verenga zvakawanda»

Musi wa13 Kukadzi, 2026, Center for Drug Evaluation (CDE) yeChina's National Medical Products Administration yakazivisa kuti mapiritsi eGFH375 akaiswa muBreakthrough Therapy Designation yekurapa varwere vane KRAS G12D-mutant non-small cell lung cancer (NSCLC) avo ...Verenga zvakawanda»

Musi wa12 Kukadzi, 2026, Center for Drug Evaluation (CDE) yeChina's National Medical Products Administration yakazivisa musi wa4 Kukadzi kuti ENHERTU® (trastuzumab deruxtecan) yakakurudzirwa kuti ibatanidzwe muBreakthrough Therapy Program kuti ishandiswe semushonga unobatsira varwere vakuru vane HER2...Verenga zvakawanda»

Dhipatimendi reBeijing South Region Oncology Hospital International rinodada nekupa varwere vekune dzimwe nyika mukana wekurapa gomarara nenzira dzemazuva ano, kusanganisira Boron Neutron Capture Therapy (BNCT) - mushonga unochinja-chinja wakatochinja hupenyu. Humbowo Hwechokwadi: Rwendo rwaMai Wu Muna 2022...Verenga zvakawanda»

Musi wa9 Kukadzi, 2026, webhusaiti yepamutemo yeCenter for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yakazivisa kuti ZL-1310 yekubaiwa jekiseni, mushonga mutsva weDLL3-targeting antibody-drug conjugate (ADC), wakarongerwa kupihwa Breakthrough Therapy Designation. Semunhu...Verenga zvakawanda»

Kune murwere wese anofamba daro refu kuti atsvage rubatsiro rwedu, tinonzwisisa zvakadzama: zvaunouya nazvo hazvisi zvinyorwa zvekurapa zvakaoma chete asiwo kuvimba netariro yemhuri yako yese. KuBeijing South Region Oncology Hospital International Department, tinoona nyaya dzakadai zuva nezuva—ho...Verenga zvakawanda»

Tichitarisana nedambudziko rekurapa gomarara remudumbu rine HER2-positive, tinonzwisisa zvizere chishuwo chenyu chekukurumidzira chesarudzo dzekurapa dzinoshanda uye dzepamusoro. Nhasi, tinokuunzirai nhau huru dzinokurudzira kubva kumunda weChina wekenza. **Kurapa Kunobudirira Kwasvika: SHR-A1811 Kunoratidza Kusasiyana...Verenga zvakawanda»

Munguva pfupi yapfuura, National Medical Products Administration yeChina yakabvumidza zviri pamutemo mushonga weAnlotinib Hydrochloride nePenpulimab naChia Tai Tianqing wekurapa chirwere chekenza chehepatocellular carcinoma. Izvi zvinoratidza chiratidzo chechigumi chakabvumidzwa cheAnlotinib Hyd...Verenga zvakawanda»

Munguva pfupi yapfuura, kurapa gomarara muChina kwasvika padanho rakakosha. Musi wa7 Ndira, 2025, National Medical Products Administration yakabvumidza zviri pamutemo mushonga mutsva weSHR-1701 kuti ushandiswe pamusika. Unoratidzwa pamwe chete nechemotherapy semushonga wekutanga wekurapa gomarara...Verenga zvakawanda»